Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial

cafead

Administrator
Staff member
  • cafead   Oct 17, 2023 at 12:02: PM
via Janssen Pharmaceuticals has announced that its Tremfya (guselkumab) demonstrated improving rates of clinical remission and endoscopic response maintained across the three-year Phase II Crohn’s disease study.

article source